A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle

Paul M. O'Neill; Steve Ward

doi:10.1002/anie.201507264

A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle

Paul M. O'Neill
, Steve Ward

Tropical Disease Biology

University of Liverpool

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Putting a stop to malaria: Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single-dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.

Original language	English
Pages (from-to)	13504-13506
Number of pages	3
Journal	Angewandte Chemie - International Edition
Volume	54
Issue number	46
DOIs	https://doi.org/10.1002/anie.201507264
Publication status	Published - 2 Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antimalarials
drug discovery
inhibitors
lead-optimization
medicinal chemistry

Access to Document

10.1002/anie.201507264

Cite this

@article{5d9b147fc9a44492991a2179ee395f40,

title = "A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle",

abstract = "Putting a stop to malaria: Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single-dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.",

keywords = "antimalarials, drug discovery, inhibitors, lead-optimization, medicinal chemistry",

author = "O'Neill, \{Paul M.\} and Steve Ward",

year = "2015",

month = nov,

day = "2",

doi = "10.1002/anie.201507264",

language = "English",

volume = "54",

pages = "13504--13506",

journal = "Angewandte Chemie - International Edition",

issn = "1433-7851",

publisher = "John Wiley and Sons Ltd",

number = "46",

}

TY - JOUR

T1 - A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle

AU - O'Neill, Paul M.

AU - Ward, Steve

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Putting a stop to malaria: Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single-dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.

AB - Putting a stop to malaria: Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single-dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.

KW - antimalarials

KW - drug discovery

KW - inhibitors

KW - lead-optimization

KW - medicinal chemistry

U2 - 10.1002/anie.201507264

DO - 10.1002/anie.201507264

M3 - Article

SN - 1433-7851

VL - 54

SP - 13504

EP - 13506

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

IS - 46

ER -

A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this